Platform uniquely combines functional genomics, pharmacology and chemistry using next generation AI/quantum technologies to offer insilico clinical trials and drug discovery as a service.

Significantly reduce drug development time and increase the probability of success in development of therapies in a wide number of targeted areas.

KEY FEATURES :

• Development of biological digital twins embedded with proprietary genetic and epigenetic analytics.
• Expected to dramatically cut costs as well as reduce development time for new therapeutics.
• Potential annual savings of billions of dollars in research and development costs for some of the world’s leading life science companies.

Key Advantages of Platform:

1. Rapid Drug Development: Insilico clinical trials enable us to expedite the drug development process by simulating and predicting drug responses, significantly reducing the time required for clinical trials and the overall cost of the trials.
2. Improved Safety and Efficacy: Insilico clinical trials enhance our understanding of drug mechanisms, allowing for the prediction of adverse effects and optimization of drug dosages, thereby increasing safety and efficacy.
3. Personalized Medicine: Our generative AI platform simulates the effects of drugs across diverse profiles of human digital twins (digital replicas of real people), enabling the development of targeted therapies and facilitating personalized medicine across disparate and diverse populations.
4. Equitable Representation: Our drug simulation process is inherently designed to include genetic, epigenetic and lifestyle variances based on ethnic and minority populations, thereby ensuring equitable representation of underserved minorities in the drug development process. We have recently partnered with a hospital group that caters almost exclusively to the underserved communities of Flint, Michigan, Southside of Chicago, etc.